

BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTS

In re Application of:

Hembrough et al.

Group Art Unit: Unassigned

Serial No: 10/086,176

Filed: February 28, 2002

For: Compositions and Methods for
Inhibiting Cellular Proliferation
Comprising TFPI Fragments

RECEIVED
#10 Plunkett
9/6/02 SEP 04 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

KILPATRICK STOCKTON LLP
1100 Peachtree Street, N.E, Ste. 2800
Atlanta, Georgia 30309-4530
Telephone: (404) 815-6500
Facsimile: (404) 815-6555
Attorney Docket No. 05213-0926 (43170-266780)

Respectfully submitted,


Sharonda R. Williams
Sharonda R. Williams
Reg. No. 52,365

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on August 28, 2002.

Sharonda R. Williams

Sharonda R. Williams - Reg. No. 52,365



BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application No.	10/086,176	
			Filing Date	02/28/2002	
			First Named Inventor	Hembrough et al.	
			Group Art Unit	1631	
Examiner Name	Unassigned				
Attorney Docket Number	05213-0296 (43170-266780)				
Sheet	1	of	15		

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ²	Kind Code ³ (if known)			
	1	4,552,888		Koppel et al.	11/12/1985	
	2	4,994,443		Folkman et al.	02/19/1991	
	3	5,001,116		Folkman et al.	03/19/1991	
	4	5,021,404		Folkman et al.	06/04/1991	
	5	5,223,409		Ladner et al.	06/29/1993	
	6	5,358,959	B1	Halperin et al.	10/25/1994	
	7	5,385,885		Gasic et al.	01/31/1995	
	8	5,589,359		Innis et al.	12/31/1996	
	9	5,653,744	B1	Khoury	08/05/1997	
	10	5,770,563		Roberts et al.	06/23/1998	
	11	5,795,865		Markland et al.	08/18/1998	
	12	5,981,471		Papathanassiou et al.	11/09/1999	
	13	6,010,880		Markland et al.	01/04/2000	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		RECEIVED SEP 04 2002 TECH CENTER 1600/2900		
				Application No.	10/086,176			
				Filing Date	02/28/2002			
				First Named Inventor	Hembrough et al.			
				Group Art Unit	1631			
				Examiner Name	Unassigned			
Sheet	2	of	15	Attorney Docket Number	05213-0296 (43170-266780)			
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	14	WO	97/09063		Chiron Corp.	03/13/1997		
	15	WO	97/35609		Juridical Foundation the Chemo-Sero- Therapeutic Research Institute	02/10/1997		No

BEST AVAILABLE COPY

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

15

Complete if Known

Application No. 10/086,176

Filing Date 02/28/2002

First Named Inventor Hembrough et al.

Group Art Unit 1631

Examiner Name Unassigned

Attorney Docket Number 05213-0296 (43170-266780)

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	16	Author: ALGIRE, G.H. et al. Title: Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants Publ: Journal of the National Cancer Institute Vol/Iss: 6 Pages: 73-85 Date: 08/1945	
	17	Author: BOK, R.A. et al. Title: Quantitative Characterization of the Binding of Plasminogen to Intact Fibrin Clots, Lysine-Sepharose, and Fibrin Cleaved by Plasmin Publ: Biochemistry Vol/Iss: 24 Pages: 3279-3286 Date: 1985	
	18	Author: BREM, H. et al. Title: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas Publ: Journal of Neurosurgery Vol/Iss: 74 Pages: 441-446 Date: 03/01/91	
	19	Author: BROZE et al. Title: Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor Publ: Biochemistry Vol/Iss: 29 (33) Pages: 7539-7546 Date: 08/21/90	
	20	Author: BROZE, G.J., Jr. et al. Title: Tissue Factor Pathway Inhibitor and the Revised Theory of Coagulation Publ: Annu. Rev. Med. Vol/Iss: 46 Pages: 103-112 Date: 1995	
	21	Author: CAO, Y. et al. Title: gro-B, a C-X-C Chemokine, is an Angiogenesis Inhibitor that Suppresses the Growth of Lewis Lung Carcinoma in Mice Publ: Journal of Experimental Medicine Vol/Iss: 182 Pages: 2069-2077 Date: 12/01/95	
	22	Author: CAO, Y. et al. Title: Kringle Domains of Human Angiostatin Publ: The Journal of Biological Chemistry Vol/Iss: 271 (46) Pages: 29461-29467 Date: 11/15/96	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	23	Author: CARDIFF, R.D. Title: Protoncopia: The Molecular Biology of Murine Mammary Hyperplasia (Abstract only) Publ: Advances in Cancer Research Vol/Iss: 42 Pages: 167-190 Date: 01/01/84	
	24	Author: CHEN, C. et al. Title: A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors Publ: Cancer Research Vol/Iss: 55 Pages: 4230-4233 Date: 10/01/1995	
	25	Author: CLEMENTS et al. Title: Kallikreins and kinins in inflammatory-like events in the reproductive tract (Abstract only) Publ: Pharmacological Research Vol/Iss: 35 (6) Pages: 537-540 Date: 06/1997	
	26	Author: CONTRINO, J. Title: In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease Publ: Nature Medicine Vol/Iss: 2 (2) Pages: 209-215 Date: 02/1996	
	27	Author: CRUM, R. et al. Title: A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment Publ: Science Vol/Iss: 230 Pages: 1375-1378 Date: 12/20/85	
	28	Author: DAVIES et al. Title: Pathobiology of Intimal Hyperplasia Publ: British Journal of Surgery Vol/Iss: 81 (4) Pages: 1254-1269 Date: 09/1994	
	29	Author: DEVARAJ et al. Title: The effects of alpha-tocopherol on critical cells in atherogenesis Publ: Current Opinion in Lipidology Vol/Iss: 9 (1) Pages: 11-15 Date: 02/1998	

Examiner Signature	Date Considered
--------------------	-----------------

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

Sheet	5	of	15
-------	---	----	----

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	30	Author: DINBERGS et al. Title: Cellular Response to Transforming Growth Factor- β 1 and Basic Fibroblast Growth Factor Depends on Release Kinetics and Extracellular Matrix Interactions Publ: The Journal of Biological Chemistry Vol/Iss: 271 (47) Pages: 29822-29829 Date: 11/22/96	
	31	Author: ENJOJI, K. et al. Title: Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly ²³¹ - Phe ²⁴⁰ , of the third Kunitz Domain is a Heparin-Binding Site Publ: Biochemistry Vol/Iss: 34 (17) Pages: 5725-5735 Date: 1995	
	32	Author: FERENCZY, A. et al. Title: The cytodynamics of endometrial hyperplasia and carcinoma Publ: Annales de Pathologie Vol/Iss: 3 (3) Pages: 189-201 Date: 09/1983	
	33	Author: FOLKMAN, J. Title: Tumor angiogenesis and tissue factor Publ: Nature Medicine Vol/Iss: 2 Pages: 167-168 Date: 02/01/96	
	34	Author: FOLKMAN, J. Title: What is the Evidence that Tumors are Angiogenesis Dependent? Publ: Journal of the National Cancer Institute Vol/Iss: 82 Pages: 4-6 Date: 01/03/90	
	35	Author: FOLKMAN, J. Title: Angiogenesis in cancer, vascular, rheumatoid and other disease Publ: Nature Medicine Vol/Iss: 1(1) Pages: 27-31 Date: 11/01/95	
	36	Author: FOLKMAN, J. Title: Angiogenesis and Its Inhibitors Publ: Important Advances in Oncology Vol/Iss: Pages: 42-62 Date: 1985	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

*Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	37	Author: FOLKMAN, J. Title: Tumor Angiogenesis: Therapeutic Implications Publ: New England Journal of Medicine Vol/Iss: 285 (21) Pages: 1182-1186 Date: 11/18/71	
	38	Author: FOLKMAN, J. et al. Title: Long-term culture of capillary endothelial cells Publ: Proceedings of the National Academy of Science USA Vol/Iss: 76 Pages: 5217-5221 Date: 10/01/79	
	39	Author: FOLKMAN, J. et al. Title: Induction of angiogenesis during the transition from hyperplasia to neoplasia Publ: Nature Vol/Iss: 339 Pages: 58-61 Date: 05/04/89	
	40	Author: FOLKMAN, J. et al. Title: Tumor Behavior in Isolated Perfused Organs in vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment Publ: Annals of Surgery Vol/Iss: 164(3) Pages: 491-502 Date: 09/01/66	
	41	Author: GIMBRONE, M.A. et al. Title: Tumor growth and neovascularization: An experimental model using the rabbit cornea Publ: Journal of the National Cancer Institute Vol/Iss: 52(2) Pages: 413-427 Date: 02/74	
	42	Author: GIMBRONE, M.A. et al. Title: Tumor dormancy in vivo by Prevention of Neovascularization Publ: Journal of Experimental Medicine Vol/Iss: 136 Pages: 261-276 Date: 1972	
	43	Author: GOOD, D.J. et al. Title: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin Publ: Proceedings of the National Academy of Science USA Vol/Iss: 87 Pages: 6624-6628 Date: 09/90	

Examiner Signature

Date Considered

¹Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 7 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

RECEIVED

SEP 04 2002

TECH CENTER 1600/290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	44	Author: GROSS, J.L. et al. Title: Modulation of Solid Tumor Growth in vivo by bFGF (Abstract only) Publ: Proceedings of the American Association of Cancer Research Vol/Iss: 31 Pages: 79 Date: 03/90	
	45	Author: GUPTA, S. et al. Title: A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4 Publ: Proceedings of the National Academy of Science USA Vol/Iss: 92 Pages: 7799-7803 Date: 08/95	
	46	Author: HAAS, A.F. et al. Title: Angiolymphoid Hyperplasia with Eosinophilia of the Hand Publ: Journal of Dermatologic Surgery and Oncology Vol/Iss: 17 Pages: 731-734 Date: 09/1991	
	47	Author: HANADA et al. Title: CARBOXYL TERMINAL BASIC AMINO ACID REGION OF TFPI PREVENTS PROLIFERATION OF HUMAN SMOOTH MUSCLE CELLS BY INHIBITING ACTIVATION OF MAP KINASE KINASE (Abstract only) Publ: Thrombosis and Haemostasis, Supplement Vol/Iss: Pages: Date: 07/2001	
	48	Author: HOLMGREN, L. et al. Title: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression Publ: Nature Medicine Vol/Iss: 1 (2) Pages: 149-153 Date: 02/95	
	49	Author: HOMANDBERG, G.A. et al. Title: Heparin-binding Fragments of Fibronectin are Potent Inhibitors of Endothelial Cell Growth Publ: American Journal of Pathology Vol/Iss: 120 Pages: 327-332 Date: 09/85	
	50	Author: INGBER, D. et al. Title: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth Publ: Nature Vol/Iss: 348 Pages: 555-557 Date: 12/06/90	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	51	Author: ISHINO et al. Title: An Autopsy Case of Cerebral Form of v. Winiwarter-Buerger's Disease with a Chronic Course of 12 Years Publ: Folia Psychiatrica Neurologica Japonica Vol/Iss: 27 (3) Pages: 207-221 Date: 1973	
	52	Author: KAMIKUBO, Y. et al. Title: Human Recombinant Tissue-Factor Pathway Inhibitor Prevents the Proliferation of Cultured Human Neonatal Aortic Smooth Muscle Cells Publ: FEBS Letters Vol/Iss: 407 Pages: 116-120 Date: 01/01/97	
	53	Author: KEHREL, B. Title: Platelet-collagen interactions Publ: Seminars in Thrombosis and Hemostasis Vol/Iss: 21 (2) Pages: 123-129 Date: 1995	
	54	Author: KHOURI, R.K. et al. Title: Local Application of Tissue Factor Pathway Inhibitor (TFPI) Inhibits Intimal Hyperplasia Induced by Arterial Interventions Publ: Surgical Forum Vol/Iss: 46 Pages: 389-391 Date: 1995	
	55	Author: KIM, K.J. et al. Title: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in Vivo Publ: Nature Vol/Iss: 362 Pages: 841-844 Date: 04/29/93	
	56	Author: KNIGHTON, D. et al. Title: Avascular and Vascular Phases of Tumour Growth in the Chick Embryo Publ: British Journal of Cancer Vol/Iss: 35 Pages: 347-356 Date: 1977	
	57	Author: KORFF et al. Title: Integration of Endothelial Cells in Multicellular Spheroids Prevents Apoptosis and Induces Differentiation Publ: The Journal of Cell Biology Vol/Iss: 143 (5) Pages: 1341-1352 Date: 11/30/98	

Examiner Signature

Date Considered

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

TECH CENTER 1600/2900

SEP 04 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	58	Author: KORFF et al. Title: Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness Publ: The FASEB Journal Vol/Iss: 15 Pages: 447-457 Date: 02/2001	
	59	Author: KORFF et al. Title: Tensional forces in fibrillar extracellular matrices control directional capillary sprouting Publ: Journal of Cell Science Vol/Iss: 112 (19) Pages: 3249-3258 Date: 10/1999	
	60	Author: KOYAMA et al. Title: Regulation and Function of an Activation-Dependent Epitope of the $\beta 1$ Integrins in Vascular Cells after Balloon Injury in Baboon Arteries and in Vitro Publ: American Journal of Pathology Vol/Iss: 148 (3) Pages: 749-761 Date: 03/1996	
	61	Author: KUZUYA et al. Title: Antioxidants Stimulate Endothelial Cell Proliferation in Culture Publ: Artery Vol/Iss: 18 (3) Pages: 115-124 Date: 1991	
	62	Author: LINDAHL, A. Title: Coagulation Inhibition and Activation in Pancreatic Cancer Publ: Cancer Vol/Iss: 70 (8) Pages: 2067-2072 Date: 10/15/92	
	63	Author: LUPU, C. et al. Title: Thrombin Induces the Redistribution and Acute Release of Tissue Factor Pathway Inhibitor from Specific Granules within Human Endothelial Cells in Culture Publ: Arteriosclerosis, Thrombosis, and Vascular Biology Vol/Iss: 15 (11) Pages: 2055-2062 Date: 11/1995	
	64	Author: MAIONE, T.E. et al. Title: Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides Publ: Science Vol/Iss: 247 Pages: 77-79 Date: 01/05/90	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

RECEIVED

SEP 04 2002

TECH CENTER 1600/290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	65	Author: MCGEE, J. et al. Title: Simultaneous Expression of Tissue Factor and Tissue Factor Pathway Inhibitor by Human Monocytes. A Potential Mechanism for Localized Control of Blood Coagulation Publ: Journal of Experimental Medicine Vol/Iss: 179 Pages: 1847-1854 Date: 06/01/94	
	66	Author: MIYAGI, Y. et al. Title: cDNA Cloning and mRNA Expression of a Serine Protease Inhibitor Secreted by Cancer Cells: Identification as Placental Protein 5 and Tissue Factor Pathway Inhibitor-2 Publ: Journal of Biochemistry Vol/Iss: 116 Pages: 939-942 Date: 1994	
	67	Author: MOSS, G.W. et al. Title: Hypothesis for a serine-protease-like domain at the COOH terminus of <i>Slowpoke</i> calcium-activated potassium channels. Publ: Journal of General Physiology Vol/Iss: 108 (6) Pages: 473-484 Date: 12/1996	
	68	Author: NAKAO-HAYASHI et al. Title: Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells Publ: Atherosclerosis Vol/Iss: 92 Pages: 141-149 Date: 02/1992	
	69	Author: NARITA, M. et al. Title: Two Receptor Systems are Involved in the Plasma Clearance of Tissue Factor Pathway Inhibitor in vivo Publ: Journal of Biological Chemistry Vol/Iss: 270 (42) Pages: 24800-24804 Date: 11/20/95	
	70	Author: NGUYEN, M. et al. Title: Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane Publ: Microvascular Research Vol/Iss: 47 Pages: 31-40 Date: 1994	
	71	Author: NGUYEN, M. et al. Title: Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients Publ: Journal of the National Cancer Institute Vol/Iss: 85 (3) Pages: 241-242 Date: 02/03/93	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	72	Author: NIWANO et al. Title: Inhibitory action of amyloid precursor protein against human Hagemanb factor (factor XII) Publ: Journal of Laboratory Clinical Medicine Vol/Iss: 125 (2) Pages: 252-256 Date: 02/1995	
	73	Author: NOVOTNY, W.F. et al. Title: Purification and Characterization of the Lipoprotein-Associated Coagulation Inhibitor from Human Plasma Publ: Journal of Biological Chemistry Vol/Iss: 264 Pages: 18832-18837 Date: 11/05/89	
	74	Author: O'REILLY et al. Title: Endogenous Inhibitors of Angiogenesis (Abstract only) Publ: Proceedings of the American Association of Cancer Research Vol/Iss: 37 Pages: 669 Date: 03/1996	
	75	Author: O'REILLY et al. Title: Angiostatin induces and sustains dormancy of human primary tumors in mice Publ: Nature Medicine Vol/Iss: 2 (6) Pages: 689-692 Date: 06/1996	
	76	Author: O'REILLY et al. Title: The Suppression of Tumor Metastases by a Primary Tumor Publ: 79th Annual Clinical Congress - San Francisco - Surgical Forum Vol/Iss: XLIV Pages: 474-476 Date: 1993	
	77	Author: O'REILLY et al. Title: Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma Publ: Cell Vol/Iss: 79 Pages: 315-328 Date: 10/21/94	
	78	Author: O'REILLY et al. Title: Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth Publ: Cold Spring Harbor Symposia on Quantitative Biology Vol/Iss: LIX Pages: 471-482 Date: 1994	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 15

Complete if Known

Application No. 10/086,176
Filing Date 02/28/2002
First Named Inventor Hembrough et al.
Group Art Unit 1631
Examiner Name Unassigned
Attorney Docket Number 05213-0296 (43170-266780)

RECEIVED

SEP 13 2002

TECH CENTER 1600/29

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	79	Author: OBESO, J. et al. Title: Methods in Laboratory Investigation/A Hemangioendothelioma-Derived Cell Line: Its Use as a Model for the Study of Endothelial Cell Biology Publ: Laboratory: Investigation Vol/Iss: 63 (2) Pages: 259-269 Date: 1990	
	80	Author: OSTERUD, B. et al. Title: Sites of Tissue Factor Pathway Inhibitor (TFPI) and Tissue Factor Expression under Physiologic and Pathologic Conditions Publ: Thrombosis and Haemostasis Vol/Iss: 73 Pages: 873-875 Date: 1995	
	81	Author: PARANGI, S. et al. Title: Antiangiogenic therapy of transgenic mice impairs <i>de novo</i> tumor growth Publ: Proceedings of the National Academy of Science USA Vol/Iss: 93 Pages: 2002-2007 Date: 03/1996	
	82	Author: PASSANITI, A. et al. Title: Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor Publ: Laboratory: Investigation Vol/Iss: 67(4) Pages: 519-528 Date: 1992	
	83	Author: PETERSON, L.C. et al. Title: Inhibitory Properties of a Novel Human Kunitz-Type Protease Inhibitor Homologous to Tissue Factor Pathway Inhibitor Publ: Biochemistry Vol/Iss: 35 Pages: 266-272 Date: 01/01/96	
	84	Author: PILGRIM et al. Title: Proliferation kultivierter Endothelzellen unter dem Einfluß von Aprotinin und 4-Aminomethylbezoesaure (no translation) Publ: Biomedica Biochimica Acta Vol/Iss: 45 (8) Pages: 1015-1019 Date: 1986	
	85	Author: RAO et al. Title: Mechanism of Antithrombin III Inhibition of Factor VIIa/Tissue Factor Activity on Cell Surfaces. Comparison With Tissue Factor Pathway Inhibitor/Factor Xa-Induced Inhibition of Factor VIIa/Tissue Factor Activity Publ: Blood Vol/Iss: 85 (1) Pages: 121-129 Date: 01/01/95	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 15

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

RECEIVED

SEP 04 2002

TECH CENTER 1600/290

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	86	Author: RASTINEJAD, F. et al. Title: Regulation of the Activity Of A New Inhibitor Of Angiogenesis By A Cancer Suppressor Gene Publ: Cell Vol/Iss: 56 Pages:345-355 Date: 02/10/89	
	87	Author: RIDRAY, S. Title: Hyperinsulinemia and smooth muscle cell proliferation Publ: International Journal of Obesity Vol/Iss: 19 Supp.1 Pages:S39-S51 Date: 05/1995	
	88	Author: SAMAMA, M.M. et al. Title: Mechanisms for the Antithrombotic Activity in Man of Low Molecular Weight Heparins (LMWHs) Publ: Haemostasis Vol/Iss: 24 Pages:105-117 Date: 01/01/94	
	89	Author: SCHUTTE et al. Title: Additional Aspects of the Effect of Kallikrein on Cell Proliferation Publ: Kinogenases: Kallikrein Symposium Physiol. Prop. Pharmacol. Ration. Vol/Iss: 4th Edition Pages:161-177 Date: 1997	
	90	Author: SPRECHER, C.A. et al. Title: Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor Publ: Proceedings of the National Academy of Science USA Vol/Iss: 91 Pages:3353-3357 Date: 04/1994	
	91	Author: SRIGLEY, J.R. Title: Small-Acinar Patterns in the Prostate Gland With Emphasis on Atypical Adenomatous Hyperplasia and Small-Acinar Carcinoma Publ: Seminars in Diagnostic Pathology Vol/Iss: 5 (3) Pages:254-720 Date: 08/1988	
	92	Author: SRIVASTAVA, A. et al. Title: The Prognostic Significance of Tumor Vascularity in Intermediate-Thickness (0.76-4.0 mm Thick) Skin Melanoma Publ: American Journal of Pathology Vol/Iss: 133 (2) Pages:419-424 Date: 11/1988	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

BEST AVAILABLE COPY

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **14** of **15**

Complete if Known

Application No.	10/086,176
Filing Date	02/28/2002
First Named Inventor	Hembrough et al.
Group Art Unit	1631
Examiner Name	Unassigned
Attorney Docket Number	05213-0296 (43170-266780)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
	93	Author: STEINHUBL, S.R. et al. Title: Local Delivery of Tissue Factor Pathway Inhibitor (TFPI) to Reduce Neointimal Proliferation in the Porcine Coronary Balloon Injury Model (Abstract only) Publ: Journal of the American College of Cardiology Vol/Iss: 29 (2) Supp. A Pages: 97557 Date: 02/1997	
	94	Author: TAYLOR, S. et al. Title: Protamine is an inhibitor of angiogenesis Publ: Nature Vol/Iss: 297 Pages: 307-312 Date: 05/27/82	
	95	Author: TEICHER, B.A. et al. Title: POTENTIATION OF CYTOTOXIC CANCER THERAPIES BY TNP-470 ALONE AND WITH OTHER ANTIANGIOGENIC AGENTS Publ: International Journal of Cancer Vol/Iss: 57 (6) Pages: 920-925 Date: 1994	
	96	Author: VOEST, E.E. et al. Title: Inhibition of Angiogenesis in Vivo by Interleukin 12 Publ: Journal of the National Cancer Institute Vol/Iss: 87 Pages: 581-586 Date: 04/19/95	
	97	Author: WARSHAWSKY, I. et al. Title: The Carboxy Terminus of Tissue Factor Pathway Inhibitor is Required for Interacting with Hepatoma Cells in Vitro and In Vivo Publ: The American Society for Clinical Investigation Vol/Iss: 95 Pages: 1773-1782 Date: 04/1995	
	98	Author: WARSHAWSKY, I. et al. Title: The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor Publ: Proceedings of the National Academy of Science USA Vol/Iss: 91 Pages: 6664-6668 Date: 07/1994	
	99	Author: WEIDNER, N. et al. Title: Tumor angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast Carcinoma Publ: Journal of the National Cancer Institute Vol/Iss: 84 Pages: 1875-1887 Date: 12/16/92	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.